Financing/analyst partners Cormark and Mackie....I was debating their involvement with an old chum earlir today and wondering why they never told the "market" Spectral had achieved the EAP ( expanded access approval ) This essentially allows the PMX to be used in US and Canadian trial sites on an ongoing basis after the trial is completed
Answers?
I also asked why the Cormark analyst kept EDT under review for 360 days ( Jun 4 / 15 - May 30 / 16) and failed to wait just one extra day so that he may include info from the company AGM which he attended
Answers?
As a matter of fact, from the time of the financing they participated in ( Feb.2/16 ), I can't find any real proof that they believed in the company or worked to share any real positives...again going back to the lack of disclosure on the EAP or compassionate care program. I am relatively new to having analyst coverage and would like a more seasoned player to explain their odd way of supporting a stock they own / owned ??
Cheers,
Sqr